Harnessing liver–heart crosstalk via extracellular vesicle-mediated hepatic delivery of microRNAs for cardiac repair
Clinical Science · 12.08.2026 · 140 (8) · 1761-1777
DOI: 10.1042/cs20250919 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, online erschienen am 30.07.2026. Verfasst von Ji-Young Kang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea. Hauptthemen laut MEDLINE: MicroRNAs, Extracellular Vesicles, Liver, Myocardium. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0). Gefördert von: Ministry of Science and ICT, South Korea (MSIT).
Abstract (Originalsprache)
Extracellular vesicles (EVs) hold great potential to deliver microRNAs (miRNAs) in vivo; however, its preferential hepatic accumulation after systemic administration hinders the therapeutic efficacy of miRNAs. Inter-organ communication via endocrine factors is crucial for maintaining physiological homeostasis. Herein, the present study leveraged liver–heart crosstalk to overcome the hepatic tropism of EVs and reframe it as a therapeutic advantage for cardiac injury. In a mouse model of angiotensin II (Ang II)-induced cardiac injury, liver tissues showed distinct changes in inflammation-related proteins compared with saline-treated controls, indicating hepatic involvement in cardiac injury. To establish a liver–heart crosstalk-based therapeutic approach, EV@miR-155 were prepared by loading miRNA-155 into mesenchymal stem cell-derived EVs. After intravenous administration, EV@miR-155 predominantly accumulated in the liver, increased hepatic miRNA-155 levels, and remodeled the hepatic microenvironment. This remodeling suppressed PPARα-mediated production of fibroblast growth factor 21, a hepatokine implicated in cardiac pathophysiology, thereby establishing a liver–heart crosstalk axis. Remarkably, EV@miR-155 treatment significantly improved cardiac function and reduced myocardial fibrosis and hypertrophy without inducing systemic toxicity (P<0.05). Therefore, the present study provides a conceptual shift by transforming the natural hepatic tropism of EVs—traditionally regarded as a delivery limitation—into a therapeutic route that enables liver–heart crosstalk-mediated cardiac repair.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.
- Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.
- GNTPharma Science and Technology Center for Health, 85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea.
ORCID-Profile: Boyoung Joung
Förderung
- Ministry of Science and ICT, South Korea (MSIT)
Zitieren
APA
Kang, J. Y., Mun, D., Yoo, G., Park, M., Lee, J., Chung, S., Yun, N., & Joung, B. (2026). Harnessing liver–heart crosstalk via extracellular vesicle-mediated hepatic delivery of microRNAs for cardiac repair. Clinical Science, 140(8), 1761-1777. https://doi.org/10.1042/cs20250919
Vancouver
Kang JY, Mun D, Yoo G, Park M, Lee J, Chung S, et al. Harnessing liver–heart crosstalk via extracellular vesicle-mediated hepatic delivery of microRNAs for cardiac repair. Clinical Science. 2026;140(8):1761-1777. doi:10.1042/cs20250919
BibTeX
@article{Kang2026,
author = {Kang, Ji-Young and Mun, Dasom and Yoo, Gyeongseo and Park, Malgeum and Lee, Jaewoong and Chung, Seyong and Yun, Nuri and Joung, Boyoung},
title = {Harnessing liver–heart crosstalk via extracellular vesicle-mediated hepatic delivery of microRNAs for cardiac repair},
journal = {Clinical Science},
year = {2026},
volume = {140},
number = {8},
pages = {1761--1777},
doi = {10.1042/cs20250919}
}
EUVIMED